With our valuable network of high quality manufacturers, we offer highly specialized products like biosimilars, liposomal technology products, nanotechnology products and orphan drugs. Apart from these highly specialized products, we offer finished dosage formulations in select therapeutic categories like cardiovasculars, neuropsychiatry, pain management and anti diabetes.
At Xeina, we are committed to providing products of the highest quality standards. All products that we offer are manufactured at EU / USFDA approved sites and are bioequivalent to the innovator products. We also ensure quality of the documentation of the products. With our in
depth regulatory understanding of various emerging markets, we ensure that we only offer those products that are complying with the dossier guidelines of that country, thereby saving time in the commercial negotiation process. We do not represent any company that does not comply with these two minimum quality requirements of EU / USFDA certification and Bioequivalence studies.
Xeina Drugs has an extensive network of clients across Latin America, Asia Pacific and Russia CIS. In Latin America, Xeina Drugs is focused on Brazil, Mexico, Colombia, Peru and Chile. With the high regulatory complexity in Brazil and Mexico, Xeina’s detailed understanding of Anvisa and Cofepris serves as an added advantage in the project management and dossier preparation stage which results in faster dossier submission. In Asia Pacific, Xeina is working with clients in Thailand, Philippines, Vietnam and Indonesia. Our clients have a strong presence across both
prescription and tender markets – be in it government or insurance tender. Russia CIS has become a mainstay of Xeina’s foray into direct on ground presence. Through joint ventures, Xeina now has its own on ground front end presence in Kazakstan, Uzbekistan, Ukraine, Georgia and Moldova and a licensing office in Russia focused on tech transfer projects.
Our Key Differentiators:
- We offer first entry generics and super specialty products like biosimilars, liposomal and nanotechnology products
- All products that we offer are manufactured at EU / USFDA approved sites and have bioequivalence studies (oral formulations)
- We have an extensive network across Latin America, Asia Pacific & Russia CIS to serve all emerging market requirements